[Peptide bioregulators: delivery and efficacy]. / Peptidnye bioregulyatory: sposob vvedeniya i effektivnost'.

PURPOSE: To compare the neuroprotective properties of retinalamin administered in different ways among open-angle glaucoma patients with compensated intraocular pressure. MATERIAL AND METHODS: The study included 498 patients (eyes) with initial, moderate and advanced stages of glaucoma. Patients were divided into 3 groups: group I (n=110) received 5 mg intramuscular and 5 mg retrobulbar injections of retinalamin; group II (n=171) received 5 mg retrobulbar injection of retinalamin; group III received 5 mg intramuscular injection of retinalamin. The overall treatment dose contained 50 mg of retinalamin. All the patients underwent tonometry and static perimetry. Patients of group II with initial glaucoma and patients of group III with moderate glaucoma also underwent contrast sensitivity tests. The examinations were conducted before the treatment, and on months 3 and 6. RESULTS: Visual acuity did not change significantly. In group I, after 3 months of treatment total threshold retinal sensitivity increased by 122 dB in patients with initial glaucoma, by 166 dB in moderate and by 124 dB in advanced glaucoma. Positive trend was observed in patients with initial and moderate stages of glaucoma by month 6. In group II, total threshold retinal sensitivity increased by 123 dB in initial glaucoma and by 110 dB in moderate; the result did not change by month 6. No significant changes were observed in patients with advanced glaucoma. In group III, total threshold retinal sensitivity increased by 142 dB in initial glaucoma, by 274 dB in moderate and by 148 dB in advanced glaucoma. Regression began on the sixth month. In group II, patients with initial glaucoma were observed to have decreased sensorimotor reaction times to achromatic stimuli within the studied areas of central visual field. In group III, patients with advanced glaucoma were also observed to have decreased sensorimotor reaction times to achromatic stimuli detected within 1° and 5° areas from the fixation point, but not in the 10° area. CONCLUSION: Retinalamin is most effective in initial and moderate glaucoma stages. Intramuscular, retrobulbar and combined administration methods have comparable efficacy.

[Evaluation of therapeutic sensitivity of retinal ganglion cells to targeted peptide bioregulator in culture]. / Otsenka terapevticheskoi chuvstvitel'nosti ganglioznykh kletok setchatki v kul'ture k targetnomu peptidnomu bioreguliatoru.

PURPOSE: To study how therapeutically sensitive retinal cell culture is to the peptide bioregulator isolated from cattle retina (Retinalamin) in models of glaucomatous optic neuropathy (GON). MATERIAL AND METHODS: The cells were isolated from the retinae separated from newborn mice. Cell sheets were disaggregated and transformed into a suspension. Removal of the off-target cell population was done by adding antibodies to deplete the cells with CD48 marker, and magnetic microbeads that attach to them. Selection of ganglion cells and obtainment of its enriched fraction was done by immunomagnetic separation. To assess the toxicity of Retinalamin, a cytotoxic test was performed on the culture of skin fibroblasts with sequential dilution of the drug into concentrations of 5.0-0.009 mg/mL. The cells were seeded at 5000 per plate well and exposed to the drug for 24 hours. To study the excitotoxic damage, the first group of plate wells with retinal cells had solution of sodium glutamate added in concentration of 20 mM, Retinalamin was added into the second group of wells in concentration of 1.25 mg/mL; both substances were added into the third group of wells. The control group consisted of intact plate wells. The cells were exposed to substances for 24 hours. Cell vitality was then evaluated using colorimetry. Optic density was measured using an automatic photometer with detection wavelength of λ=490 nm. RESULTS: The cell culture achieved by immunomagnetic separation is mixed and consists of ganglion and glial cells. Retinalamin does not display significant cytotoxicity in any of the studied concentrations. The excitotoxic damage caused significant decrease of the amount of viable cells in the culture (9% of the control wells). The concomitant addition of glutamate and 1.25 mg/mL Retinalamin resulted in a 51.6% increase in the amount of viable cells. The intergroup differences were statistically significant by Student's t-test. CONCLUSION: Retinalamin is not cytotoxic. The concomitant addition of glutamate and Retinalamin reliably decreases the toxic action of glutamate on isolated retinal cells.